Articles

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Combos Lead Excitement in BRAF+ Melanoma, but More Pain Points are Ready to be Tackled

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Uveal Melanoma

Treatment pairing dabrafenib and trametinib could have expanded benefits for patients with melanoma.

Combination Treatment Improves Relapse-Free Survival Time 

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

Optimize Risk, Management of Pigmented Lesions in Pediatric Patients

A recent study found states' Medicare per-beneficiary spending between actinic keratosis and skin cancer differs widely.

Medicare Spending on Skin Cancer, AK Varies Widely

Videos

Neelam Vashi, MD, FAAD, explains the results of her cross-sectional survey investigating melanoma awareness among different racial and ethnic groups. 

Disparities in melanoma awareness

Recently, PRAME (preferentially expressed antigen in melanoma) immunohistochemical staining has shown its usefulness in distinguishing benign from malignant melanocytic cell populations, offering another color to the canvas in the quest for a more definitive diagnosis of melanoma.  

Utility of PRAME staining in identifying malignant transformation of melanocytic nevi

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Mohs micrographic presents challenges in kids 

Podcasts

Neelam Vashi, M.D., FAAD, discusses the publication of her cross-sectional survey in the Journal of the American Academy of Dermatology regarding how different racial and ethnic groups possess various levels of melanoma awareness. 

The Cutaneous Connection- Episode 11: Racial Disparities in Melanoma Awareness

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.